An Open, Multi Center Trial to Evaluate the Efficacy and Safety of High-Dose,Pulsatile Erlotinib/Gefitinib for Advanced Non-Small Cell Lung Cancer Patients After Failure of Standard Dose EGFR-TKIs
Phase of Trial: Phase II
Latest Information Update: 03 May 2019
Price : $35 *
At a glance
- Drugs Erlotinib (Primary) ; Gefitinib (Primary)
- Indications Non-small cell lung cancer
- Focus Adverse reactions; Therapeutic Use
- 03 May 2017 Planned End Date changed from 1 Aug 2015 to 1 Dec 2017.
- 03 May 2017 Planned primary completion date changed from 1 Aug 2015 to 1 Dec 2017.
- 29 Jun 2015 Planned End Date changed from 1 Mar 2015 to 1 Aug 2015 as reported by ClinicalTrials.gov record.